CN109837300A - A method of for improving ALPPS induction hepatic tissue growth rate - Google Patents
A method of for improving ALPPS induction hepatic tissue growth rate Download PDFInfo
- Publication number
- CN109837300A CN109837300A CN201910160981.9A CN201910160981A CN109837300A CN 109837300 A CN109837300 A CN 109837300A CN 201910160981 A CN201910160981 A CN 201910160981A CN 109837300 A CN109837300 A CN 109837300A
- Authority
- CN
- China
- Prior art keywords
- alpps
- pcmv
- hepatic tissue
- growth rate
- hgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of methods for improving ALPPS induction hepatic tissue growth rate, include the following steps, step 1: in the ALPPS first stage performs the operation, tourniquet is placed on the omphaloschisis of patient and liver hits exactly the position split, and illness side liver branch of portal vein is ligatured merely, step 2: use feeling state Escherichia coli DH-5 α expands pCMV-HGF plasmid.This is used to improve the method for ALPPS induction hepatic tissue growth rate, the position split by omphaloschisis and liver center that tourniquet suspention is placed into patient, and illness side liver branch of portal vein is ligatured merely, the blood flow of non-illness side liver can be made to increase, the various nutriments and a variety of Auto-regulators for promoting hepatic cell growth being rich in portal vein are that the rapid growth of FLR provides material base, again by injecting pCMV-HGF plasmid, promoting hepatocyte growth factor solution and insulin solutions to patient, the growth rate of ALPPS induction hepatic tissue can be effectively improved.
Description
Technical field
It is specially a kind of for improving ALPPS induction hepatic tissue growth rate the present invention relates to operation on liver technical field
Method.
Background technique
The residual liver volume deficiency of Hepatectomy is to limit the principal element of liver tumour radical excision, therefore some patientss lose
Operative treatment chance is gone, normal liver can be resistant to 70% resection, and the liver for merging cirrhosis can only be resistant to 50% and cut
Except amount, equal FLR hyperplasia is needed after the ALPPS first stage, the existing postoperative FLR hyperplasia efficiency of APPS is not high enough, suffers from
The operation that person needs to wait longer time that can carry out second stage, causes some patientss to lose the chance of operation, is
This is it is proposed that a kind of method for improving ALPPS induction hepatic tissue growth rate.
Summary of the invention
In view of the deficiencies of the prior art, the present invention provides a kind of for improving the side of ALPPS induction hepatic tissue growth rate
Method, the hepatic tissue growth rate for solving ALPPS first stage postoperative patient cause the operation of patient's second stage to be not achieved slowly excessively
The problem of best effect.
To achieve the above object, the invention provides the following technical scheme: it is a kind of for improving ALPPS induction hepatic tissue growth
The method of rate, comprising the following steps:
Step 1: tourniquet is placed on the omphaloschisis of patient and liver hits exactly the position split in the ALPPS first stage performs the operation
It sets, and ligatures illness side liver branch of portal vein merely；
Step 2: use feeling state Escherichia coli DH-5 α expands pCMV-HGF plasmid, the DNA of pCMV-HGF plasmid is extracted
And measure its concentration and purity；
Step 3: the pCMV-HGF plasmid for taking out doses is injected into physiological saline and is sufficiently mixed the two；
Step 4: the solution prepared in above-mentioned steps is arrived by syringe intravenous injection after the first operating stage
Patient's is internal；
Step 5: patient is daily within a period of time that the ALPPS first stage performs the operation between the operation of ALPPS second stage
Intravenous drip promoting hepatocyte growth factor solution；
Step 6: taking out suitable hepatocyte growth factor and insulin, hepatocyte growth factor is mixed with insulin
Together；
Step 7: patient stops the method note that injection promoting hepatocyte growth factor solution passes through portal catheterization Micropump two days later
Enter the insulin solutions mixed in previous step.
Preferably, the modes of emplacement of the tourniquet is suspension method placement.
Preferably, the Pcmv-HGF plasmid is recombined human HGF expression plasmid, and Pcmv-HGF plasmid includes people HGF's
Full-length cDNA.
Preferably, the pCMV-HGF plasmid quality for being dissolved in physiological saline is 15-25 μ g, and physiological saline is 1.5-1.8ml.
Preferably, the time for being injected intravenously the pCMV-HGF prepared is 5-10s.
Preferably, the promoting hepatocyte growth factor solution of the intravenous drip be 80-110mg hepatocyte growth promoting factor and
250ml5% glucose injection is equipped.
Preferably, the amount of hepatocyte growth factor is 1.8-2.3mg/kg, and the amount of insulin is 1.8-2.3U/h.
It has the beneficial effect that:
This is used to improve the method for ALPPS induction hepatic tissue growth rate, by the navel that tourniquet suspention is placed into patient
It splits and liver hits exactly the position split, and ligature illness side liver branch of portal vein merely, the blood of non-illness side liver can be made
Flow increases, and the various nutriments and a variety of Auto-regulators for promoting hepatic cell growth being rich in portal vein are FLR's
Rapid growth provides material base, then by injecting pCMV-HGF plasmid, promoting hepatocyte growth factor solution and pancreas to patient
Island element solution can effectively improve the growth rate of ALPPS induction hepatic tissue.
Specific embodiment
Based on the embodiments of the present invention, those of ordinary skill in the art are obtained without making creative work
The every other embodiment obtained, shall fall within the protection scope of the present invention.
The present invention provides a kind of technical solution: a method of for improve ALPPS induction hepatic tissue growth rate, comprising with
Lower step:
Step 1: tourniquet is placed on the omphaloschisis of patient and liver hits exactly the position split in the ALPPS first stage performs the operation
It sets, the modes of emplacement of tourniquet is suspension method placement, plays the Doppler flow mapping blocked between residual liver and tumor load liver, makes
It obtains FLR growth rate to increase, and ligatures illness side liver branch of portal vein merely, the blood flow of non-illness side liver can be made
Increase, the various nutriments and a variety of Auto-regulators for promoting hepatic cell growth being rich in portal vein are the quick of FLR
Growth provides material base,
Step 2: use feeling state Escherichia coli DH-5 α expands pCMV-HGF plasmid, the DNA of pCMV-HGF plasmid is extracted
And its concentration and purity are measured, Pcmv-HGF plasmid is recombined human HGF expression plasmid, and Pcmv-HGF plasmid includes people HGF's
Full-length cDNA promotes patient's so that the HGF high of patient's body is expressed by the internal injection Pcmv-HGF plasmid toward patient
Liver regeneration,
Step 3: the pCMV-HGF plasmid for taking out doses is injected into physiological saline and is sufficiently mixed the two, it is molten
In physiological saline pCMV-HGF plasmid quality be 15-25 μ g, and physiological saline be 1.5-1.8ml；
Step 4: the solution prepared in above-mentioned steps is arrived by syringe intravenous injection after the first operating stage
Patient's is internal, and the time for being injected intravenously the pCMV-HGF prepared is 5-10s；
Step 5: patient is daily within a period of time that the ALPPS first stage performs the operation between the operation of ALPPS second stage
Intravenous drip promoting hepatocyte growth factor solution, the promoting hepatocyte growth factor solution of intravenous drip are 80-110mg hepatocyte
Auxin and 250ml5% glucose injection are equipped；
Step 6: taking out suitable hepatocyte growth factor and insulin, hepatocyte growth factor is mixed with insulin
Together, the amount of hepatocyte growth factor is 1.8-2.3mg/kg, and the amount of insulin is 1.8-2.3U/h, and insulin is liver
Trophic factors, through portal vein perfusion insulin compared with the stimulated hepatic cell regeneration effect through PeV medication after partial hepatectomy
More significant, trans-portal vein medication can maintain higher insulin concentration, and the drug concentration of Continuous Perfusion is more stable, and hepatocyte is again
Raw effect is obvious, also small to blood sugar influence；
Step 7: patient stops the method note that injection promoting hepatocyte growth factor solution passes through portal catheterization Micropump two days later
Enter the insulin solutions mixed in previous step so that postoperative liver function is faster restored, residual liver regeneration speed faster.
It should be noted that, in this document, relational terms such as first and second and the like are used merely to a reality
Body or operation are distinguished with another entity or operation, are deposited without necessarily requiring or implying between these entities or operation
In any actual relationship or order or sequence.Moreover, the terms "include", "comprise" or its any other variant are intended to
Non-exclusive inclusion, so that the process, method, article or equipment including a series of elements is not only wanted including those
Element, but also including other elements that are not explicitly listed, or further include for this process, method, article or equipment
Intrinsic element.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
A variety of variations, modification, replacement can be carried out to these embodiments without departing from the principles and spirit of the present invention by understanding
And modification, the scope of the present invention is defined by the appended.
Claims (7)
1. a kind of method for improving ALPPS induction hepatic tissue growth rate, it is characterised in that: include the following steps:
Step 1: tourniquet is placed on the omphaloschisis of patient and liver hits exactly the position split in the ALPPS first stage performs the operation, and
Simple ligation illness side liver branch of portal vein；
Step 2: use feeling state Escherichia coli DH-5 α expands pCMV-HGF plasmid, the DNA of pCMV-HGF plasmid and survey are extracted
Its fixed concentration and purity；
Step 3: the pCMV-HGF plasmid for taking out doses is injected into physiological saline and is sufficiently mixed the two；
Step 4: the solution prepared in above-mentioned steps is injected intravenously by syringe to patient after the first operating stage
It is internal；
Step 5: patient the ALPPS first stage perform the operation ALPPS second stage operation between a period of time in once a day
Intravenous drip promoting hepatocyte growth factor solution；
Step 6: taking out suitable hepatocyte growth factor and insulin, hepatocyte growth factor and insulin are blended in one
It rises；
Pass through in the method injection of portal catheterization Micropump two days later step 7: patient stops injection promoting hepatocyte growth factor solution
The insulin solutions mixed in one step.
2. a kind of method for improving ALPPS induction hepatic tissue growth rate according to claim 1, it is characterised in that:
The modes of emplacement of the tourniquet is suspension method placement.
3. a kind of method for improving ALPPS induction hepatic tissue growth rate according to claim 1, it is characterised in that:
The Pcmv-HGF plasmid is recombined human HGF expression plasmid, and Pcmv-HGF plasmid includes the full-length cDNA of people HGF.
4. a kind of method for improving ALPPS induction hepatic tissue growth rate according to claim 1, it is characterised in that:
The pCMV-HGF plasmid quality for being dissolved in physiological saline is 15-25 μ g, and physiological saline is 1.5-1.8ml.
5. a kind of method for improving ALPPS induction hepatic tissue growth rate according to claim 1, it is characterised in that:
The time for being injected intravenously the pCMV-HGF prepared is 5-10s.
6. a kind of method for improving ALPPS induction hepatic tissue growth rate according to claim 1, it is characterised in that:
The promoting hepatocyte growth factor solution of the intravenous drip is 80-110mg hepatocyte growth promoting factor and 250ml5% glucose injection
Liquid is equipped.
7. a kind of method for improving ALPPS induction hepatic tissue growth rate according to claim 1, it is characterised in that:
The amount of hepatocyte growth factor is 1.8-2.3mg/kg, and the amount of insulin is 1.8-2.3U/h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910160981.9A CN109837300A (en) | 2019-03-04 | 2019-03-04 | A method of for improving ALPPS induction hepatic tissue growth rate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910160981.9A CN109837300A (en) | 2019-03-04 | 2019-03-04 | A method of for improving ALPPS induction hepatic tissue growth rate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109837300A true CN109837300A (en) | 2019-06-04 |
Family
ID=66885327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910160981.9A Pending CN109837300A (en) | 2019-03-04 | 2019-03-04 | A method of for improving ALPPS induction hepatic tissue growth rate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109837300A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2798133C1 (en) * | 2022-09-15 | 2023-06-15 | государственное автономное учреждение здравоохранения "Кузбасская клиническая больница скорой помощи им. М.А.Подгорбунского" (ГАУЗ ККБСМП) | Method of prevention of post-resection liver failure |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104388383A (en) * | 2014-08-29 | 2015-03-04 | 中国人民解放军第二军医大学 | Long-term in-vitro culture and directional differentiation system and method for liver stem cell |
| CN107075515A (en) * | 2013-11-22 | 2017-08-18 | 米纳治疗有限公司 | C/EBP α compositions and application method |
-
2019
- 2019-03-04 CN CN201910160981.9A patent/CN109837300A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107075515A (en) * | 2013-11-22 | 2017-08-18 | 米纳治疗有限公司 | C/EBP α compositions and application method |
| CN104388383A (en) * | 2014-08-29 | 2015-03-04 | 中国人民解放军第二军医大学 | Long-term in-vitro culture and directional differentiation system and method for liver stem cell |
Non-Patent Citations (3)
| Title |
|---|
| SHI ET AL: "A preliminary study of ALPPS procedure in a rat model", 《NATURE》 * |
| ZHANG ET AL: "Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): A new strategy to increase resectability in liver surgery", 《INTERNATIONAL JOURNAL OF SURGERY》 * |
| 龚作炯等: "生长激素和肝细胞生长因子对大鼠肝大部切除后再生的影响", 《世界华人消化杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2798133C1 (en) * | 2022-09-15 | 2023-06-15 | государственное автономное учреждение здравоохранения "Кузбасская клиническая больница скорой помощи им. М.А.Подгорбунского" (ГАУЗ ККБСМП) | Method of prevention of post-resection liver failure |
| RU2819517C1 (en) * | 2023-10-06 | 2024-05-21 | Государственное автономное учреждение здравоохранения "Кузбасская клиническая больница скорой помощи им. М.А. Подгорбунского" (ГАУЗ ККБСМП) | Method of portal-caval blood flow separation of right lobe of liver in order to create conditions for its resection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Macdougall et al. | Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit | |
| Glaeser et al. | Emergency intraosseous infusions in children | |
| JP2021506952A (en) | GIP / GLP1 agonist composition | |
| Eroglu et al. | A clinical comparison of equal concentration and volume of ropivacaine and bupivacaine for interscalene brachial plexus anesthesia and analgesia in shoulder surgery | |
| Thomas et al. | Postinfusion phlebitis | |
| JP2004524278A5 (en) | ||
| White et al. | Intravenous valproate associated with significant hypotension in the treatment of status epilepticus | |
| Berk et al. | The treatment of shock with beta adrenergic blockade | |
| Finsen | Reduced pain when injecting lidocaine | |
| Messing et al. | Technical hazards of using nutritive mixtures in bags for cyclical intravenous nutrition: comparison with standard intravenous nutrition in 48 gastroenterological patients. | |
| Atabek et al. | Pancreaticoduodenectomy without homologous blood transfusion in an anemic Jehovah's Witness | |
| CN109837300A (en) | A method of for improving ALPPS induction hepatic tissue growth rate | |
| Ertug et al. | Comparison of two different techniques for brachial plexus block: infraclavicular versus axillary technique | |
| Heavner et al. | Continuous brachial plexus blockade using an axillary catheter for treatment of accidental intra-arterial injections | |
| Baker et al. | Intraarterial infusion chemotherapy for head and neck cancer using a totally implantable infusion pump | |
| Chang et al. | Acute myeloid leukemia associated with acute myocardial infarction and dural sinus thrombosis: the possible role of leukemia-related hyperhomocysteinemia | |
| CN105434471A (en) | Stem cell preparation for treating diabetes and preparation method of stem cell preparation | |
| CN111494310A (en) | Preparation and application method of local anesthetic | |
| Pharm et al. | Infusion of high doses of undiluted etoposide through central venous catheters during preparation for bone marrow transplantation | |
| JP2006514643A5 (en) | ||
| Kumar et al. | Successful isolated small bowel transplantation in short bowel syndrome: Anaesthetic considerations | |
| Chinitz et al. | Internal arteriovenous fistulae for home dialysis | |
| Lee et al. | Pain on Injection of Propofol: The Effect of Injectate Temperature. | |
| SU876116A1 (en) | Method of stopping blood bleeding from internal organs | |
| Kim et al. | Successful management of potential non-heart-beating donor with extracorporeal membrane oxygenation: A case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190604 |